Camp4 Therapeutics reported FY25 GAAP EPS of -$2.65, missing expectations, but ended with a robust $109.5 million cash position. Liquidity was significantly strengthened by private placements, equity ...

Feb. 23 (UPI) --The pretrial hearings for former Philippine President Rodrigo Duterte are set to begin at the International Criminal Court Monday, though he has refused to attend. Duterte, 80, said he ...

Formula 1 has trialled a new race start procedure – involving flashing blue grid panels – at pre-season testing in Bahrain. Following discussions in a meeting of the F1 Commission on Wednesday, 10 ...

Duterte's defence claims cognitive decline, ICC disagrees ICC prosecutors allege Duterte funded and armed death squads Duterte says police were instructed to kill only in self-defence Duterte's ...

Add Yahoo as a preferred source to see more of our stories on Google. Former Philippine president Rodrigo Duterte gestures as he delivers a message during the proclamation rally for his political ...

ALBUQUERQUE, N.M. — Actor and director Timothy Busfield is expected to go before a judge for the second time on Tuesday. In this pre-trial detention hearing, Busfield will find out if he’s staying ...

WASHINGTON — A young child has died from the complications associated with the flu, the Virginia Department of Health (VDH) reported on Thursday. According to VDH, this is the first ...

NEW YORK — After nearly three weeks of testimony, pretrial suppression hearings in Luigi Mangione's New York state case have finally concluded. The 27-year-old was arrested one year ago for the murder ...

Dan Raby, the senior digital producer for CBS News Atlanta, has been covering everything happening around Georgia for more than a decade. The father of the 14-year-old boy accused of carrying out a ...

For two weeks now, a rotating cast of police officers have arrived to a Manhattan courtroom to lay out exactly what happened the day Luigi Mangione was arrested and accused of killing UnitedHealthcare ...

(RTTNews) - IGC Pharma, Inc. (IGC), a clinical-stage biotechnology company, has announced that it has reached 65% patient enrolment in its ongoing Phase 2 CALMA trial evaluating IGC-AD1 for the ...